Khan Siddiqui - 09 Feb 2022 Form 4 Insider Report for Hyperfine, Inc. (HYPR)

Role: Chief Medical Officer and CSO
Signature: /s/ Neela Paykel, Attorney-in-Fact
Issuer symbol: HYPR
Transactions as of: 09 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 11 Feb 2022, 19:23:30 UTC
Previous filing: 23 Dec 2021
Next filing: 31 Mar 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HYPR	Stock Option (right to buy)	Award	$0	+110,000		$0.000000	110,000	09 Feb 2022	Class A Common Stock	110,000	$3.90	Direct	F1
transaction	HYPR	Stock Option (right to buy)	Award	$0	+74,000		$0.000000	74,000	09 Feb 2022	Class A Common Stock	74,000	$3.90	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying this option vest as to 25% on the date of grant, and 2.083% at the end of each month thereafter beginning on February 31, 2022, subject to Dr. Siddiqui's continued service through the applicable vesting date; provided that any vesting of the award will be delayed if as of the applicable vesting date a registration statement on Form S-8 registering shares under the registrant's 2021 Equity Incentive Plan has not yet been filed with the Securities and Exchange Commission, and in such event the number of options vesting on the first scheduled vesting date following the filing of the registration statement will also include any delayed vesting options.
F2	The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Dr. Siddiqui's continued service through the applicable vesting date.

Content

The shares underlying this option vest as to 25% on the date of grant, and 2.083% at the end of each month thereafter beginning on February 31, 2022, subject to Dr. Siddiqui's continued service through the applicable vesting date; provided that any vesting of the award will be delayed if as of the applicable vesting date a registration statement on Form S-8 registering shares under the registrant's 2021 Equity Incentive Plan has not yet been filed with the Securities and Exchange Commission, and in such event the number of options vesting on the first scheduled vesting date following the filing of the registration statement will also include any delayed vesting options.

The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Dr. Siddiqui's continued service through the applicable vesting date.